ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,187.67
0.00%
Dow Jones
39,056.39
0.44%
US Dollar vs MXN
16.8995
-0.04%
Brent Oil
83.56
0.84%
Bitcoin
61,555.01
-1.25%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Sanofi (SNY)

  7. Sanofi (SNY) Noticias

SNY

Sanofi (SNY)

Sanofi
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:SNY
FechaHoraFuenteTítuloSímboloCompañía
25/04/202406:52IH Market NewsSouthwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on EarningsNASDAQ:SNYSanofi
19/04/202406:31IH Market NewsParamount’s Shares Surge Following Sony and Apollo’s Joint Bid; ISS Backs Berkshire Hathaway Director Re-election, and MoreNASDAQ:SNYSanofi
23/02/202413:02Edgar (US Regulatory)Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).NASDAQ:SNYSanofi
23/02/202410:15Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:SNYSanofi
15/02/202411:09Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SNYSanofi
14/02/202414:57Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SNYSanofi
25/01/202413:29GlobeNewswire Inc.Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)NASDAQ:SNYSanofi
23/01/202405:05Dow Jones NewsSanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion -- UpdateNASDAQ:SNYSanofi
23/01/202404:40IH Market NewsWall Street Highlights: Vroom Shuts Down Online Car Sales, Ericsson Warns of Decline Outside China, and MoreNASDAQ:SNYSanofi
23/01/202400:00PR Newswire (US)Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2BNASDAQ:SNYSanofi
09/01/202401:14Dow Jones NewsSanofi Names Brian Foard Head of Specialty-Care UnitNASDAQ:SNYSanofi
21/12/202301:25Dow Jones NewsSanofi Ends Drug Program After Late-Stage Trial in Lung Cancer FailsNASDAQ:SNYSanofi
19/12/202306:28Dow Jones NewsInnate Pharma Shares Rise after Sanofi Exercises Licensing OptionNASDAQ:SNYSanofi
12/12/202304:50IH Market NewsHasbro Job Cuts, Oracle’s Stock Decline, Google’s Epic Antitrust Loss, and MoreNASDAQ:SNYSanofi
11/12/202316:18Dow Jones NewsSanofi Terminates Agreement with Maze Therapeutics Following FTC OppositionNASDAQ:SNYSanofi
11/12/202300:50Dow Jones NewsSanofi Sees Improvement in Trial Results of Cancer Drug SarclisaNASDAQ:SNYSanofi
07/12/202301:34Dow Jones NewsSanofi Myeloma Drug Sarclisa Met Primary Goal in Late-Stage TrialNASDAQ:SNYSanofi
07/12/202301:20Dow Jones NewsSanofi Sees Annual Sales From New Pharma Assets Above $10.8 Billion by 2030NASDAQ:SNYSanofi
06/12/202307:20Dow Jones NewsTrending: Merck's Multiple Sclerosis Drug Misses Expectations in Late-Stage TrialsNASDAQ:SNYSanofi
06/12/202304:14Dow Jones NewsMerck Shares Slump After Multiple Sclerosis Drug Fails in Late-Stage TrialsNASDAQ:SNYSanofi
30/11/202308:23Dow Jones NewsTeva Closes Collaboration Deal With Sanofi on IBD TreatmentNASDAQ:SNYSanofi
30/11/202307:30Business WireTeva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease TreatmentNASDAQ:SNYSanofi
27/11/202309:31Dow Jones NewsTrending: Sanofi's Notus Trial Meets Primary EndpointNASDAQ:SNYSanofi
27/11/202301:40Dow Jones NewsSanofi Says Notus Phase 3 Trial of Dupixent Met Primary EndpointNASDAQ:SNYSanofi
27/11/202300:30GlobeNewswire Inc.Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious DiseaseNASDAQ:SNYSanofi
07/11/202315:01AllPennyStocks.comOrphan Drugs Worth $64 Billion by 2028 and This Micro Cap Could Have One by That TimeNASDAQ:SNYSanofi
07/11/202307:56Dow Jones NewsSanofi Under Preliminary Probe in France Over Possible Market Manipulation, Source SaysNASDAQ:SNYSanofi
07/11/202306:10IH Market NewsTuesday’s Wall Street Highlights: WeWork, UBS, Sanofi, Alteryx, Intel, and more.NASDAQ:SNYSanofi
06/11/202306:50Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SNYSanofi
02/11/202311:15PR Newswire (US)Sanofi honors 10 advocacy organizations promoting health equity solutions in underserved U.S. communitiesNASDAQ:SNYSanofi
 Showing the most relevant articles for your search:NASDAQ:SNY

Su Consulta Reciente

USOTC
BNPQY
BNP Paribas (QX)
USOTC
ADDYY
Adidas (QX)
FX
EURMXN
Euro vs MXN
NASDAQ
QQQ
Invesco QQQ Trust Series 1
USOTC
RHHBY
Roche (QX)
NASDAQ
AMZN
Amazon.com
COIN
BTCUSD
Bitcoin
PM
XAUUSD
Gold vs US Dollar
NYSE
CVX
Chevron
NYSE
MRK
Merck
NASDAQ
TSLA
Tesla
AMEX
XLV
Health Care Select Sector
NYSE
JPM
JP Morgan Chase
CCOM
US30
US 30
NYSE
XOM
Exxon Mobil
AMEX
XLF
Financial Select Sector
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados